Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Natural killer cell

Phase 2Biologic

SSt. Jude Children's Research Hospital

Natural killer cell is one of 126 biologic programs targeting Leukemia. It is currently in Phase 2.

4

Indications

6

Total Trials

2

Active Trials

125

Competitors

Pipeline

Status by Indication[3][1]

Indication

LeukemiaActive, not recruiting

NeuroblastomaActive, not recruiting

Precursor B-Cell Acute Lymphoblastic LeukemiaActive, not recruiting

Biliary Tract CancerActive, not recruiting

LeukemiaPhase 1

Active, not recruiting

NeuroblastomaPhase 2

Active, not recruiting

Precursor B-Cell Acute Lymphoblastic LeukemiaPhase 2

Active, not recruiting

Biliary Tract CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

508 competitors in Leukemia

#DrugCompanyPhaseTrials

Trexall

Alnylam Pharmaceuticals

Fludara

Cytoxan

BBaxter Healthcare Corporation

Rituxan

Vepesid

Decadron

AAspen Global Incorporated

Novantrone

Leukine

Cellcept

Oncovin

EEastern Cooperative Oncology Group

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Neuroblastoma3 trials

Therapy for Children With Advanced Stage Neuroblastoma

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT01857934·153 enrolled

Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00698009·1 enrolled

Quadruple Immunotherapy for Neuroblastoma

Recruiting·HHong Kong Children's Hospital·Phase 2·NCT05754684·29 enrolled

Biliary Tract Cancer1 trial

Phase 1 Clinical Trial to Evaluate the Safety of Allogeneic NK Cell ("SMT-NK") Cell Therapy in Advanced Biliary Tract Cancer

Completed·YYonsei University·Phase 1·NCT03358849·9 enrolled

Precursor B-Cell Acute Lymphoblastic Leukemia1 trial

Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

Completed·SSt. Jude Children's Research Hospital·Phase 2·NCT01700946·80 enrolled

Leukemia1 trial

A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01287104·34 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Natural killer cell. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Natural killer cell compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Natural killer cell. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — St. Jude Children's Research Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: SSt. Jude Children's Research Hospital

Related News